31 unknown, 22 completed, 16 recruiting, 9 not yet recruiting. 67 Phase 2, 25 Phase 1, 6 Phase 3, 3 Not applicable, 1 Early Phase 1.
Follow surufatinib: new trials by email Literature Review of surufatinib trials Research Report on surufatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC Surufatinib Plus Iparomlimab and Tuvonralimab and AG Chemotherapy, Gemcitabine plus Capecitabine, Modified FOLFIRINOX - Borderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic Cancer | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 56 | 2026-09-01 | 2026-09-22 |
| Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC Radiotherapy, Concurrent chemotherapy, Tislelizumab - NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Sun Yat-sen University | 160 | 2026-06-01 | 2026-07-01 |
| Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer Surufatinib, Toripalimab, mFOLFIRINOX - Pancreatic Cancer Resectable | Phase 2 | Not yet recruiting | Sun Yat-sen University | 30 | 2026-03-31 | 2026-03-13 |
| Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study surufatinib, Somatostatin Analogs - Neuroendocrine Tumors | Active not recruiting | West China Hospital | 500 | 2026-03-06 | 2026-04-16 | |
| Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer surufatinib + gemcitabine + nab-paclitaxel, gemcitabine + nab-paclitaxel - Pancreatic Cancer, Adult | Phase 3 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 106 | 2026-03-03 | 2026-07-10 |
| Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System surufatinib - Neuroendocrine Neoplasms (Tumours) | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 35 | 2026-01-01 | 2025-12-12 |
| Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms Surufatinib - Neuroendocrine Tumors, Neuroendocrine Neoplasms | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 350 | 2025-11-11 | 2025-12-19 |
| Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors Surufatinib Combined With Standard chemotherapy, Surufatinib - Pulmonary Neuroendocrine Tumor | Phase 2 | Recruiting | Shanghai Chest Hospital | 96 | 2025-09-22 | 2026-01-22 |
| Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer Surufatinib, Tislelizumab, Concurrent Chemotherapy - Surufatinib, Tislelizumab | Phase 2 | Recruiting | Sun Yat-sen University | 80 | 2025-07-20 | 2025-07-25 |
| Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer Chemotherapy, Immunotherapy, Angio-immuno kinase inhibitor - Toripalimab, Surufatinib | Phase 2 | Recruiting | Sun Yat-sen University | 47 | 2024-11-30 | 2026-03-03 |
| Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma Envafolimab and Surufatinib - Unresectable Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-10-01 | 2024-10-24 |
| Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma Surufatinib, Sintilimab, Oxaliplatin - Gastric Cancer, Gastro Esophageal Junction Cancer | Phase 2 | Active not recruiting | Fudan University | 20 | 2024-09-30 | 2026-08-05 |
| Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer Surufatinib, Gemcitabine, Cisplatin - Advanced Biliary Tract Cancer | Phase 2 | Recruiting | Dai, Guanghai | 35 | 2024-08-15 | 2024-11-27 |
| Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation Surufatinib, Serplulimab, standard chemotherapy - ESCC, Biliary Tract Cancer | Phase 2 | Not yet recruiting | RenJi Hospital | 80 | 2024-08-10 | 2024-07-31 |
| A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors Surufatinib, Placebo - Pancreatic Neuroendocrine Tumor | Phase 2 | Terminated | Changhai Hospital | 6 | 2024-06-17 | 2026-06-11 |
| Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation Surufatinib, Tislelizumab - NSCLC | Phase 2 | Not yet recruiting | National Cancer Center, China | 29 | 2024-06-01 | 2024-05-16 |
| Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer Paclitaxel - Ovarian Cancer | Phase 2 | Recruiting | Anhui Provincial Cancer Hospital | 74 | 2024-05-25 | 2024-11-27 |
| A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD Surufatinib 250mg/d qd once daily - Advanced Pancreatic Cancer | Phase 2 | Unknown | Rui-hua Xu, MD, PhD | 37 | 2024-05-22 | 2024-05-08 |
| A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC Adebrelimab - Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-05-10 | 2024-04-19 |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine - Metastatic Pancreatic Cancer | Phase 2 / Phase 3 | Recruiting | Hutchmed | 502 | 2024-05-08 | 2026-09-17 |
Showing 20 of 90. Sign in to see all of them.
Neuroendocrine Tumors (10) · Pancreatic Neoplasms (10) · Small Cell Lung Carcinoma (7) · Biliary Tract Neoplasms (5) · Cholangiocarcinoma (4) · Sarcoma (4) · Stomach Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Neoplasms (3) · Osteosarcoma (3) · Ovarian Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Neuroendocrine (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2)
Hutchison Medipharma Limited (17) · Sun Yat-sen University (11) · Hutchmed (7) · Fudan University (6) · Tianjin Medical University Cancer Institute and Hospital (5) · Fujian Cancer Hospital (3) · Peking University (3) · Qilu Hospital of Shandong University (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Shanghai Zhongshan Hospital (3) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (3) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (1) · Anhui Provincial Cancer Hospital (1) · Bai-Rong Xia (1)
China (71) · United States (9) · Italy (2) · France (1) · Germany (1) · Japan (1) · Norway (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Jihui Hao, M.D. (2) · Song Gao, M.D. (2) · Songhua Fan, MD (2) · Wenjing Jiang (2) · William Schelman, MD (2) · Bai-Rong Xia, MD (1) · Bairong Xia, Doctor (1) · Bin Zhang, MD (1) · Binhao Li, PhD (1) · Chen Yu, Dr. (1) · Dongsheng Zhang, PhD (1) · Fuxiang Zhou, MD,PhD (1) · Gang Jin, Doctor (1) · Hui Liu, Professor (1) · Huihua Xiong (1)
PMID 35344750, PMID 35489301, PMID 40306120, PMID 19704057, PMID 21306237, PMID 25014687, PMID 26703889, PMID 31555796, PMID 32800383, PMID 32966810, PMID 32966811, PMID 35166929, PMID 37074571, PMID 38237373, PMID 38713205, PMID 39327433, PMID 39624833, PMID 40812353, PMID 41039600, PMID 41077611, PMID 41349529, PMID 42129445